
|Articles|June 10, 2019
Neuroprotective implant for treatment of glaucoma in phase II trial
Author(s)Julianne Mobilian
Here's the latest innovations at Neurotech Pharmaceuticals, Inc.
Advertisement
Rich Small, CPA, CEO of
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves NDA labeling supplement allowing re-administration of iDose TR
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
Dr. Mali’s top 5 predictions in ophthalmology for 2026
4
Cloudbreak Pharma completes FDA end-of-phase-2 meeting for CBT-004 in pinguecula
5



























